Ramipril
- Generic Name
- Ramipril
- Brand Names
- Altace, Altace HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N2O5
- CAS Number
- 87333-19-5
- Unique Ingredient Identifier
- L35JN3I7SJ
- Background
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
- Indication
For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
- Associated Therapies
- -
Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2007-08-16
- Lead Sponsor
- Università degli Studi dell'Insubria
- Target Recruit Count
- 80
- Registration Number
- NCT00517322
- Locations
- 🇮🇹
University of Insubria-Department of Clinical Medicine, Varese, Italy
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 229
- Registration Number
- NCT00502242
- Locations
- 🇿🇦
Pfizer Investigational Site, Cape Town, Western Cape, South Africa
To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2009-07-16
- Lead Sponsor
- Universiti Sains Malaysia
- Target Recruit Count
- 66
- Registration Number
- NCT00489229
- Locations
- 🇲🇾
School of Medical Sciences, University Sains Malaysai, Kota Bharu, Kelantan, Malaysia
Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- University of Vigo
- Target Recruit Count
- 120
- Registration Number
- NCT00473174
- Locations
- 🇪🇸
Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00437463
- Locations
- 🇭🇰
Sanofi-Aventis, Hong Kong, Hong Kong
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- Conditions
- Interventions
- Drug: CaptoprilDrug: EnalaprilDrug: LisinoprilDrug: RamiprilDrug: TrandolaprilDrug: BisoprololDrug: CarvedilolDrug: Metoprolol succinateDrug: CandesartanDrug: ValsartanDrug: EplerenoneDrug: SpironolactoneDrug: DiureticsDrug: HF treatment according to Swedish guidelinesProcedure: Blood samplesProcedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT00391846
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 422
- Registration Number
- NCT00389519
- Locations
- 🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇦🇷Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina
🇦🇷Hospital General Interzonal "Dr. José Penna", Buenos Aires, Argentina
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 901
- Registration Number
- NCT00368277
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
- Conditions
- First Posted Date
- 2006-08-18
- Last Posted Date
- 2007-03-09
- Lead Sponsor
- Pacific Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT00366119
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, 28 Yeongeon-dong, Jongno-gu, Korea, Republic of
Ramipril - Hypertension
- Conditions
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1008
- Registration Number
- NCT00325806
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.